home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Masimo Corporation - Common Stock (NQ:MASI)

130.06 -1.01 (-0.77%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Masimo Corporation - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stocks That Hit 52-Week Lows On Wednesday ↗

February 16, 2022

On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...

Via Benzinga

Is Masimo 'Crazy Like A Fox' For Spending $1.03 Billion To Buy Sound United? ↗

February 16, 2022

Investors were left scratching their heads after Masimo announced the buyout.

Via Investor's Business Daily

Mid-Day Market Update: Crude Oil Rises 2%; EIA Reports Unexpected Rise In Crude Inventories ↗

February 16, 2022

US stocks traded lower midway through trading on Wednesday ahead of the release of Fed minutes.

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

February 16, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower Ahead Of Fed Minutes ↗

February 16, 2022

US stocks opened on a downbeat note this morning following the release of several economic reports.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 16, 2022 ↗

February 16, 2022

Upgrades According to Compass Point, the prior rating for Comerica Inc (NYSE:CMA) was changed from Neutral to Buy. Comerica earned $1.66 in the fourth quarter, compared to $1.49...

Via Benzinga

Looking Into Masimo's Return On Capital Employed ↗

February 16, 2022

According to Benzinga Pro, during Q4, Masimo (NASDAQ:MASI) earned $68.26 million, a 18.15% increase from the preceding quarter. Masimo also posted a total of $327.58 million in sales, a 6.56% increase...

Via Benzinga

Masimo Stock Plunges After Q4 Results, Sound United Deal ↗

February 16, 2022

Masimo Corp's (NASDAQ: MASI) Q4 product revenue increased 11% Y/Y to $327.6 million, or 11.5% on a constant currency basis, beating the consensus of $320.93 million...

Via Benzinga

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗

February 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

February 16, 2022

We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

10 Biggest Price Target Changes For Wednesday ↗

February 16, 2022

Needham raised Airbnb, Inc. (NASDAQ: ABNB) price target from $210 to $220. Airbnb shares rose 3.1% to $185.70 in pre-market trading.

Via Benzinga

Masimo: Q4 Earnings Insights ↗

February 15, 2022

Masimo (NASDAQ:MASI) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Masimo beat estimated earnings by...

Via Benzinga

Sound United Enters into Agreement to Be Acquired by Masimo Corporation

February 15, 2022

From Sound United, LLC

Via Business Wire

Masimo Reports Fourth Quarter and Full-Year 2021 Financial Results and Announces Agreement to Acquire Sound United

February 15, 2022

From Masimo

Via Business Wire

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

A Preview Of Masimo's Earnings ↗

February 14, 2022

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an...

Via Benzinga

Masimo Adds Telehealth to Its SafetyNet® Telemonitoring System

February 10, 2022

From Masimo

Via Business Wire

Earnings Scheduled For February 15, 2022 ↗

February 15, 2022

Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.

Via Benzinga

Temple University Hospital Adopts Masimo Centroid™

February 07, 2022

From Masimo

Via Business Wire

7 Superior Stocks That Smart Investors Will Buy on the Dip ↗

February 07, 2022

The recent sell-off presents long-term investors with many robust stocks to buy on the dip. These seven provide a start.

Via InvestorPlace

Retrospective Study Finds That Masimo SET® Pulse Oximetry Has No Difference in Accuracy or Bias Between Black People and White People

January 17, 2022

From Masimo

Via Business Wire

Restrospective Study Finds That Masimo SET® Pulse Oximetry Has No Difference in Accuracy or Bias Between Black People and White People

January 17, 2022

From Masimo

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

January 14, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Masimo Announces Select Preliminary Full-Year 2021 Financial Results and 2022 Guidance

January 11, 2022

From Masimo Corporation

Via Business Wire

New Study Suggests That Masimo SedLine® Brain Function Monitoring May Aid Early Identification of Patients at Risk of Developing Postoperative Delirium

December 13, 2021

From Masimo

Via Business Wire

Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India

November 29, 2021

From Masimo

Via Business Wire

Masimo to Present in Piper Sandler 33rd Annual Healthcare Conference

November 23, 2021

From Masimo

Via Business Wire

New Study Finds That Use of Masimo SedLine® PSi and DSA May Significantly Reduce Postoperative Delirium

November 15, 2021

From Masimo

Via Business Wire

Masimo to Present in Stifel 2021 Virtual Healthcare Conference

November 11, 2021

From Masimo

Via Business Wire

Masimo Root® with a Multimodal Brain Monitoring Algorithm May Improve Postoperative Neurocognition in Elderly Patients

November 08, 2021

From Masimo

Via Business Wire

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com